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It is now well established that mitochon-
dria are critical targets in many, if not
most, examples of apoptotic cell death,
sequestering factors (cytochrome c, AIF,
Smac/Diablo) that are necessary for acti-
vating cytoplasmic caspase cascades
and additional nuclear events of apopto-
sis (Olsen and Kornbluth, 2001). These
previously bland organelles are also the
principal site of action for the cell death
and survival functions of the Bcl-2 pro-
tein family.
In this issue of Cancer Cell, Fantin et
al. (2002) describe a mitochondrial toxin
selective for tumor cells, known as F16,
which they identified using high-through-
put cell-based screening of a chemical
library. The concept of a mitochondrial
basis for killing tumor cells has been
around since the early part of last centu-
ry, built upon metabolic studies demon-
strating general differences in metabolic
control between cancers and normal
cells. The most consistently reported
metabolic disturbance in tumor cells is
abnormally high rates of glycolysis,
which is demonstrated now on a daily
basis in the clinic with the use of fluo-
rodeoxyglucose PET scanning to diag-
nose recurrent or residual malignant dis-
ease. The question of mitochondrial
involvement in a metabolic phenotype of
cancer has been more difficult to pin
down.
Warburg (1956) initially posited that
mitochondrial oxidative phosphorylation
was defective in tumor cells, and that this
initial insult led to gradual and compen-
satory increases in glycolytic ATP produc-
tion as the central event of cell transfor-
mation. He predicted that treatments pro-
ducing mitochondrial injury, of a general
nature, would strike a greater blow
against cancer cells due to their already
compromised respiratory state, than
against normal cells. Various defects in
cancer mitochondria have been
described, including reduced capacity for
oxidation of NADH-linked substrates,
reduced expression and/or activity of
ATPase and OXPHOS complexes, and
mtDNA mutations, without a general 
pattern. There is also the possibility that
high rates of glycolysis may suppress res-
piration, known as the Crabtree effect,
without implicating defective mitochondria
(Sussman et al., 1980).
Interventions designed to attack
metabolic susceptibilities of tumor cells
have included glycolytic inhibitors (2-
deoxyglucose), membrane pore activa-
tors (lonidamine), and thiol-active
chemicals (arsenicals). More recently,
screening of a combinatorial library of
compounds based on natural benzopy-
ran inhibitors of mitochondrial complex I
yielded several novel compounds with
pronounced cytostatic effects against a
cancer cell line panel (Nicolaou et al.,
2000). Polyketide inhibitors of F(0)F(1)-
ATPase scored among the top 0.1% of
37,000 compounds tested for selective
cytotoxicity in the NCI 60 cell line panel
(Salomon et al., 2000). Unlike these
studies, Fantin et al. (2002) employed
cell-based screening without presuppos-
ing a mitochondrial target. Thus, the F16
compound was selected out of 16,000
small molecules in a Chembridge library
for its selective inhibition of cell prolifera-
tion of a mouse mammary epithelial cell
line expressing a constitutively active
neu oncogene. This approach lends fur-
ther credence to the prior observations
that mitochondriotoxic agents can have
anticancer activity.
The structure of F16 is characteristic
of a delocalized lipophilic cation (DLC),
many examples of which are concentrat-
ed in mitochondria. Fluorescent proper-
ties of several DLCs, including F16,
make them useful probes of mitochon-
drial membrane potential.The archetypal
DLC, the Kodak laser dye rhodamine-
123, was initially reported in the early
1980s to accumulate selectively in carci-
nomas and chemically transformed cell
lines (Davis et al., 1985) and newer gen-
eration rhodacyanine dyes have similar
properties. Extended treatment of carci-
noma cell lines with Rh-123 leads to
eventual cytoplasmic redistribution of the
dye, indicative of mitochondrial toxicity,
and cell death, with sparing of normal
epithelial cells.
Preferential killing of cancer cells
with these compounds correlates well
with their selective uptake in mitochon-
dria within cancer cells. Thus, the width
of the therapeutic window for these com-
pounds as potential anticancer agents is
likely to be controlled by factors affecting
intramitochondrial and also intracellular
drug levels. Partitioning of a cation
across the inner mitochondrial mem-
brane follows the Nernst equation
∆Ψ = 60 log {[C+]m / [C+]c},
and, as concluded by the authors, pre-
dicts that cells with higher mitochondrial
membrane potentials will accumulate
increased mitochondrial concentrations
of the cation [C+]m (Rottenberg and Wu,
1998). Although an association of higher
resting mitochondrial membrane poten-
tials with cancer cells is often cited, this
finding is clearly incompatible with the
reports of structural and genetic abnor-
malities in cancer cell mitochondria. More
likely, aerobic glycolysis (the Warburg
effect) in cancer cells may compete for
ADP and phosphate with oxidative phos-
phorylation, resulting in a significant
increase in resting ∆Ψm as mitochondria
shift from phosphorylating to nonphos-
phorylating conditions. As shown by this
group, addition of F16 to normal liver
mitochondria causes cyclosporin A-de-
pendent mitochondrial swelling, indica-
tive of permeability transition pore (PTP)
activation. Indeed, selectivity of Rh-123
has not been demonstrated with isolated
mitochondria from cancer cells, suggest-
ing that the mitochondrial susceptibility
in cancer cells is interwoven with cellular
metabolic control mechanisms. Mito-
chondrial uptake of F16 and other DLCs
also reflects distribution across the plas-
ma membrane, according to the plasma
membrane potential, ∆Ψp, which may
vary between cancer and normal cell
populations. It will be important and fas-
cinating to examine how the individual
oncogenes with unique F16 sensitivity
profiles reported by Fantin et al. (2002)
affect these metabolic parameters.
In the absence of a discrete enzyme
or structural protein inhibited by
F16 (chemical genetics), alternative
approaches must be used to validate
mitochondria as the critical targets of
F16. Fantin et al. (2002) report that treat-
ment of cancer cells with the uncoupler
FCCP to depolarize mitochondria abolish-
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es any additive toxicity from F16, consis-
tent with a requirement for mitochondrial
accumulation of the compound. Dose-
response measurements at low concen-
trations of F16 (100 nM) should demon-
strate concordance between the direct
mitochondrial effects of F16 (uncoupling,
increased O2 consumption) and cell toxic-
ity. Structure-activity relationships may
demonstrate that cytotoxicity of a series of
related compounds is correlated with rela-
tive mitochondrial uptake. Despite strong
correlative evidence, nonmitochondrial
sites of action can emerge to complicate
conclusions about mechanism. MKT-077,
a rhodacyanine DLC dye entered into
Phase I clinical trials, has since been
reported to have direct effects on addi-
tional targets, including telomerase inhibi-
tion, crosslinking of F actin, and reactiva-
tion of wild-type p53 via binding the
hsp70 family member, mot-2 (mortalin)
(Maruta et al., 1999; Naasani et al.,
1999; Wadhwa et al., 2000).
The central importance of mito-
chondria in apoptotic cell death path-
ways offers up several molecular tar-
gets in mitochondria that are highly
expressed in cancer cells. Foremost
among these are the Bcl-2-related sur-
vival proteins, Bcl-2 and Bcl-xL. There
are now several examples of small mol-
ecules that bind to the hydrophobic
groove of these proteins and either dis-
place proapoptotic family members
(Bax, Bak) from a heterodimeric com-
plex or alter membrane topology of the
survival proteins (Degterev et al., 2001;
Tzung et al., 2001). Although the report
by Fantin et al. (2002) does not examine
the effect of Bcl-2 expression on F16
cytotoxicity, a separate group compared
the ability of Bcl-2 to rescue L929 cells
treated with neutral hydrophilic, anionic
lipophilic, and cationic lipophilic photo-
sensitizers (Klein et al., 2001). Over-
expression of Bcl-2 sensitized L929
cells to the cationic drug, Victoria Blue
BO, even in the dark, associated with
increased mitochondrial uptake. Since
the proposed functions of the Bcl-2 anti-
apoptotic proteins include regulation of
mitochondrial membrane permeability,
compounds with selective accumulation
in mitochondria, including F16, may
represent another approach to eradi-
cate cancer cells expressing high levels
of Bcl-2/Bcl-xL and resistant to standard
chemotherapy.
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Functions of p53 suppress critical consequences of damage 
and repair in the initiation of cancer
A pivotal study reveals a long-sought-after mechanism for gene amplification and provides important implications for
oncogenesis.
One of the most frequent and mystifying
types of abnormalities observed in
human carcinomas is the amplification
of large genomic regions associated
with complex chromosomal rearrange-
ments (complicons). These abnormali-
ties are believed to be the functional
basis for tumor progression and drug
resistance both in vivo and in vitro
(Kuehl and Bergsagel, 2002; Federspiel
et al., 1984). In a recent publication by
Zhu et al., the molecular dissection of
these complicated structures in the
experimental generation of lymphomas
has illuminated a molecular mechanism
of gene amplification and several factors
that can modulate this process. As the
result of a long series of fundamental
observations, culminating in a recent
elegant study (Zhu et al., 2002), the Alt
laboratory has identified several of the
major determinants that generate the
intermediates in this process and has
been able to propose a mechanism.
They show that, in a setting where V(D)J
recombination is initiated, deficiencies in
both p53 function and nonhomologous
end-joining abilities conspire to gener-
ate complex genomic rearrangements.
In this system, the chromosomal
rearrangement is initiated by RAG
(recombination-activating genes)-medi-
ated recombination that catalyzes a
